不同剂量瑞舒伐他汀对急性心肌梗死患者经皮冠状动脉介入治疗术后的影响

Effects of different doses of rosuvastatin on patients with acute myocardial infarction after percutaneous coronary intervention

目的探讨不同剂量瑞舒伐他汀对急性心肌梗死患者经皮冠状动脉介入治疗术后的影响。方法分析肇庆市第一人民医院2017年2月~2018年3月收治的72例急性心肌梗死经皮冠状动脉介入治疗患者临床资料,依据随机数字表法进行分组,治疗Ⅰ组(常规瑞舒伐他汀剂量)30例和治疗Ⅱ组(高瑞舒伐他汀剂量)42例。观察两组患者术前、术后7d高敏C反应蛋白(hs-CRP)、肿瘤坏死因子-α(TNF-α)、白介素-6(IL-6)、左室收缩末期内径(LVESD)、左室舒张末期内径(LVEDD)、左室射血分数(LVEF)情况。结果两组患者术前hs-CRP、TNF-α、IL-6、LVESD、LVEDD、LVEF比较,两组患者术后7d LVEDD比较,差异均无统计学意义(P> 0.05),术后7d,两组患者hs-CRP、TNF-α、IL-6、LVESD均低于同组术前,LVEF均高于同组术前,治疗Ⅱ组患者hs-CRP、TNF-α、IL-6、LVESD均低于治疗Ⅰ组,LVEF均高于治疗Ⅰ组,差异均有统计学意义(P <0.05)。结论高剂量瑞舒伐他汀在急性心肌梗死患者经皮冠状动脉介入治疗术应用后,改善炎性介质和心功能更加明显,值得临床推广应用。

Objective To investigate the effects of different doses of rosuvastatin on patients with acute myocardial infarction after percutaneous coronary intervention. Methods The clinical data of 72 patients underwent percutaneous coronary intervention for acute myocardial infarction admitted and treated at our hospital from February 2017 to March 2018 were analyzed, and the patients were divided into the treatment Ⅰ group(conventional rosuvastatin dose) with 30 patients and the treatment Ⅱ group(high rosuvastatin dose) with 42 patients using the random number table method. The high-sensitivity C-reactive protein(hs-CRP), tumor necrosis factor-α(TNF-α), interleukin-6(IL-6), left ventricular end systolic diameter(LVESD), left ventricular end diastolic diameter(LVEDD), and left ventricular ejection fraction(LVEF) were observed before operation and at 7 d after operation in both groups of patients. Results There was no statistically significant difference in hs-CRP, TNF-α, IL-6, LVESD, LVEDD, and LVEF between both groups of patients before operation, and in LVEDD between both groups of patients at 7 d after operation(P > 0.05);At 7 d after operation, hs-CRP, TNF-α, IL-6, and LVESD in both groups of patients were all lower than those in the same group before operation, while LVEF was higher than that in the same group before operation;hs-CRP, TNF-α, IL-6, and LVESD of patients in the treatment Ⅱ group were all lower than those in the treatment I group, while LVEF was higher than that in the treatment Ⅰ group, with statistically significant difference(P < 0.05). Conclusion After the application of high-dose rosuvastatin in patients undergoing percutaneous coronary intervention for acute myocardial infarction, the improvement of inflammatory mediators and cardiac function is more obvious, which is worthy of clinical promotion and application.